Brain

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit

SANTA ANA, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage…

9 months ago

The ADDF’s Diagnostics Accelerator Authors New Paper on Ocular Biomarker Landscape, Highlighting Ocular Tests as a Tool for Early Detection of Alzheimer’s Disease

New findings published in Alzheimer's & Dementia suggest blood biomarkers are expected to become the standard method for diagnosing Alzheimer's,…

9 months ago

World-first ISO Requirements for child-friendly services for victims of violence launched today during the 58th Human Rights Council

GENEVA, March 12, 2025 /PRNewswire/ -- In a historic move to combat the global crisis of violence against children, ISO has…

9 months ago

Life Time Brings Trusted, Proven Line of LTH-Branded Supplements to Amazon

Rigorously tested, research-backed LTH protein powders, electrolytes, fish oil and more now available CHANHASSEN, Minn., March 12, 2025 /PRNewswire/ -- Life…

9 months ago

Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing

Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignanciesVANCOUVER, British Columbia, March…

9 months ago

Prime Biome Reviews And Complaints: A Detailed Study Released That’s Needs to Be Adopted for Which Type of Peoples?

ST. PETERSBURG, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- This is a comprehensive examination of the groundbreaking research behind Prime…

9 months ago

Lindus Health and Sooma Medical announce pivotal device clinical trial for treatment of MDD

BOSTON, March 11, 2025 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science…

9 months ago

NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain

Submission for New Intended Use That Leverages Company’s Patented OneRF® Technology Platform Expected in May 2025  EDEN PRAIRIE, Minn., March…

9 months ago

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

LONDON, March 11, 2025 (GLOBE NEWSWIRE) -- Kaerus Bioscience (www.kaerusbio.com), a clinical-stage biopharmaceutical company created by Medicxi for the development…

9 months ago